Skip to main content
TipRanks
Go Ultimate75% OFF

Verici Dx Plc (63V) AI Stock Analysis

0 Followers
DE:63V

Verici Dx Plc

(Frankfurt:63V)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong revenue growthRapid revenue expansion indicates growing commercial traction for Verici Dx’s transplant-focused diagnostic products. If this trajectory continues, a larger installed customer base and rising test adoption could improve operating leverage and create a stronger foundation for future profitability.
Negative Factors
Persistent widening lossesThe company has not yet converted strong revenue growth into profitability, and the wider 2025 net loss shows that expenses are rising faster than the current revenue base can support. Persistent losses may delay self-funded growth and increase the need for additional capital.

Verici Dx Plc (63V) vs. iShares MSCI Germany ETF (EWG)

-40%-20%0%20%40%60%DE:63V+53.85%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 11.66M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.4
Beta (1Y)
-2.14
Revenue Growth
72.40%
EPS Growth
84.78%
Country
Germany
Employees
23
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Verici Dx Plc Business Overview & Revenue Model

Company Description

Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline...

Verici Dx Plc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:63V against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:EKFGB:EKF64NeutralGBP 102.28M41.383.58%―2.26%-57.04%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:GDRGB:GDR49NeutralGBP 14.45M-0.78-1044.57%―65.60%74.84%
GB:ABDXGB:ABDX46NeutralGBP 21.48M-15.45-34.31%―30.42%43.16%
GB:RENXGB:RENX44NeutralGBP 35.87M-3.21675.00%―――
GB:OBDGB:OBD40UnderperformGBP 15.46M-0.26-451.74%―33.37%86.41%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:63VGB:EKFGB:GDRGB:OBDGB:RENXGB:ABDXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:63V and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:63VVerici Dx Plc0.020.0153.85%
GB:EKFEKF Diagnostics Holdings24.00-0.60-2.44%
GB:GDRGenedrive plc0.85-0.09-9.48%
GB:OBDOxford BioDynamics0.10-0.18-62.50%
GB:RENXRenalytix Plc OTC5.20-1.55-22.96%
GB:ABDXAbingdon Health PLC8.501.2517.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.